Forward P/S Multiple: TELA Bio Inc. (TELA)

TELA Bio - graphic logo of issuer TELA

Geopolitical risks and logistics disruptions are limiting TELA Bio, Inc. (TELA) access to raw materials and markets, as clearly demonstrated by the company's forward P/S chart, where the metric stands at 0.50. Fundamental stability is provided by innovative OviTex implants with a unique structure and expansion into the reconstructive surgery niche through biosynthetic solutions that minimize the risk of complications.

TELA Bio - TELA Market Cap to Projected Revenue (period 07/04/2022 - 11/14/2026)

Summary analytical data breakdowns for telabio.com (TELA)

- market price and analyst price targets:
Price Chart TELA Bio|TELA - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization TELA Bio, Inc.|TELA - Total Enterprise Value
- issuer book value statistics:
Book Value per Share TELA Bio|TELA - Accounting Capitalization|Market Capitalization to Book Value Ratio telabio.com|TELA - Company Total Asset Base
- debt and liquidity data:
Total Debt to Capital TELA Bio, Inc.|TELA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital TELA Bio|TELA - Company Aggregate Debts|Debt to Book Capitalization Ratio TELA Bio, Inc.|TELA - Company Long-Term Debt|Company Current Liabilities TELA Bio|Quick Ratio telabio.com
- financial results and valuation multiples details:
TELA - Company Net Income|Expected Profit TELA Bio, Inc.|TELA - Market Cap to Net Income Ratio|Projected Price to Earnings TELA Bio|TELA - PEG Multiple|EV/EBITDA Multiple TELA Bio, Inc.|TELA - Operating income before deduction of amortization|Earnings per share for the last twelve months TELA Bio|TELA - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months telabio.com|TELA - Net earnings per share growth this year|Earnings growth forecast for next year TELA Bio, Inc.
- sales and revenue indicators:
TELA - Company Total Revenue|Company Projected Revenue TELA Bio|TELA - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple TELA Bio, Inc.
Fundamental company analysis:TELA (TELA Bio Corp)
Product sample of telabio.com

Investors utilize this tool to determine the market value of a business relative to its future cash flows. The forward price-to-sales ratio compares current market capitalization with expected revenue for the following year, identifying whether an asset is undervalued or carries hidden risks. For TELA Bio, Inc. (TELA), low forward price-to-sales values may overlook the high loyalty of surgeons to the unique OviTex hybrid meshes.

Who TELA Bio, Inc. competes with

Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward Price-to-Revenue Multiple Picard Group PMI|Forward P/S Multiple SRDX (Surmodics, Inc.)|Forward P/S Multiple senseonics.com SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (SANUWAVE Health, Inc.) - Forward Price-to-Revenue Multiple|Outset Medical Corp - Forward Price to Sales|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio lensar.com LNSR|Price-to-Projected Revenue Ratio AVITA Medical (RCEL)|profoundmedical.com (PROF) - Projected Price to Revenue|Baird Medical - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP TMS SA EDAP|Bovie Medical - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical Ltd ICCM|pulmonx.com (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue CTSO (CytoSorbents Corporation)|Price-to-Projected Revenue Ratio Sensus Healthcare Corp|Forward Price-to-Revenue Multiple Zynex Corp (ZYXI)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Inspira Technologies IINN|ICU: Market Cap to Projected Revenue|IRIX: Forward Price-to-Revenue Multiple|Intelligent Bio Solutions - Price to Expected Revenue Ratio|XAIR (beyondair.net) - Forward Price-to-Revenue Multiple|PFSA: Price to Expected Revenue Ratio|SSKN (STRATA Skin Sciences Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio glucotrack.com GCTK|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|Price-to-Projected Revenue Ratio VERO (Venus Concept Corporation)|Forward P/S Multiple NUWE (Nuwellis, Inc.)|Forward P/S Multiple aethlonmedical.com AEMD|ASXC: Forward Price-to-Revenue Multiple|Forward Price to Sales AVGR (Avinger Inc.)|BSGM: Forward P/S Multiple|CUTR (Cutera Inc) - Price-to-Projected Revenue Ratio|KNW (Know Labs, Inc.) - Forward P/S Multiple|inarimedical.com (NARI) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Nevro (NVRO)|RSLS - Market Cap to Future Revenue Ratio|Silk Road Medical Inc. - Forward Price-to-Revenue Multiple